Dr. Tsu-An Hsu is the CEO and CSO of Anbogen Therapeutics. He has blended R&D experiences in biopharma companies and research institutes, e.g. Human Genome Sciences, Merck & Co and National Health Research Institutes. He identified existing drugs for inhibition of SARS-CoV during the SARS outbreak in 2003.

Joe Hsueh is the President and Chief Operating Officer （COO） of Anbogen Therapeutics. He leads finance operations and business development, leveraging his expertise in venture capital and the pharmaceutical industries across Taiwan, China, and the U.S. As the former COO of ACT Genomics, he spearheaded finance operations, sales, marketing, and business development teams to identify and capitalize on business opportunities for future growth. Mr. Hsueh brings over 15 years of experience in operations, finance, and business development from his tenure at the reputable biopharmaceutical company, TaiGen Biotechnology in Taiwan. During his time at TaiGen, he successfully led the company through two series of financing, co-conducted another series, and secured a total of $114 million USD within seven years. He also inked an out-licensing deal and was involved in various tasks and business networking within the biopharmaceutical and pharmaceutical industries. Before joining TaiGen Biotechnology, Mr. Hsueh worked for Chengxin VC, where he led fundraising efforts for six companies in the United States and Taiwan. He holds an MBA from Fairleigh Dickinson University in the USA and a B.A. in Microbiology from Soochow University in Taiwan.

Dr. Hsieh serves as the Special Medical Advisor for Anbogen Therapeutics, overseeing the companys global clinical development portfolio since 2020. He is also the Chief Medical Officer for IMPACT Therapeutics in Shanghai. Over the past three years, Dr. Hsieh has played a pivotal role in shaping the clinical development strategy for the companys innovative assets. He has established a fully functional clinical research team and advanced IMPACTs compounds, creating one of the most comprehensive clinical-stage portfolios in the synthetic lethality area globally. Under his leadership, IMPACT successfully obtained US FDA IND approval for four clinical trials with innovative study designs, including two first-in-human studies with Wee1 and ATR inhibitors. Prior to joining Anbogen, Dr. Hsieh served as the Chief Medical Officer of ASLAN Pharmaceuticals, where he led the clinical development team to initiate nine clinical trials, including five multinational trials （one pivotal trial） and four single-country trials, ranging from phase 1 to global pivotal studies. Dr. Hsieh also held a Medical Advisor position at Novartis Oncology, where he was responsible for clinical studies of the hematology pipeline, including both global and regional studies. Dr. Hsieh obtained his M.D. from National Yang-Ming University in Taiwan and is board certified in internal medicine, hematology, oncology, and blood and marrow transplantation. He is an active member of the Taiwan Oncology Society, ASCO, ESMO, and CSCO.

Angus Wu has extensive experience in business development, strategic partnerships, global market access, marketing, and commercialization within the fields of precision cancer medicine and in vitro diagnostics. Prior to joining Anbogen, Angus served as the Associate Vice President of ACT Genomics, where he led partnering and M&A activities with Canon Medical, oncology-focused biopharmaceutical companies, and diagnostic firms. His efforts resulted in substantial revenue from technology licensing and regional partnerships across Asia.

Endy Yang is the Vice President of Finance and Accounting at Anbogen. With extensive experience in the financial field of the biotech and pharmaceutical industries, Mr. Yang is well-versed in corporate financing and capital markets. Prior to joining Anbogen, he spent approximately 20 years at TWi Pharmaceuticals, Inc. and TaiGen Biotechnology Co., Ltd., where he was involved in transactions such as IPOs, M&As, capital restructuring, fundraising, and the design, execution, and maintenance of employee equity incentive tools, as well as corporate governance matters. Before his tenure in the biotech and pharmaceutical industries, Mr. Yang worked for Taiwan Securities Inc., Ltd. and Taiwan High Speed Rail Corporation. He holds a graduate degree in Finance and an undergraduate degree in Business Administration, both from National Taiwan University.

Dr. Tan joined Anbogen Therapeutics in 2022. Before joining Anbogen, Dr. Tan held a leadership role in the Medical Informatics and Translational Medicine departments at ACT Genomics, a service provider specializing in cancer genomics and bioinformatics. Dr. Tan has extensive experience in conducting clinical research with physicians in Taiwan, Hong Kong, Japan, and Singapore. He has accumulated profound knowledge, experience, and expertise in cancer genomics and precision oncology, particularly in biomarker exploration. Dr. Tan earned a B.A. in Medical Technology from National Taiwan University and a Ph.D. in Molecular and Cell Biology from National Defense Medical Center. He completed a Postdoctoral Fellowship at Academia Sinica.

Shan Shan Lin is the Vice President of Clinical Operations at AnBogen. Ms. Lin has extensive experience in clinical operations, clinical quality management, and quality assurance. Before joining AnBogen, she served at global CRO companies such as Covance, EPSI, and ICON, as well as global pharmaceutical companies like Aventis and MSD. With over 20 years of experience, Ms. Lin has been involved in clinical research planning, execution, and quality management.

Dr. Joe Chuan Shih is the co-founder and chair of SAB of Anbogen Therapeutics. He is the venture partner at Lilly Asia Ventures. He is the co-inventor and led the development of Alimta®, the blockbuster drug at Eli Lilly and bozitinib at CrownBio.

Dr. Hsing-Pang Hsieh’s lab specializes in drug discovery and developing on novel anticancer drugs “From Bench to Bedside”. He has published 125 scientific journals including 29 papers published in J. Med. Chem., top-one in the field of medicinal chemistry, and obtained 63 composition patents granted worldwide. More importantly, I invented three clinical candidates:（A） DBPR104, which was licensed to SynCore Bio, was completed Phase II clinical trial in Taiwan. （B） DBPR112, which was licensed to AnBogen Therapeutics, was approved for IND by US FDA and TFDA on April 8 and August 23, 2016 and is undergoing Phase I clinical trial in Taiwan since July 2017; （C） DBPR114 was approved for IND by US FDA on July 20, 2017. Dr. Hsing-Pang Hsieh co-founder and SAB member of Anbogen Therapeutics. He is the deputy director of Biomedical Translation Research Center （BioTReC）/ National Biotechnology Research Park （NBRP） in Taiwan. He is the inventor of sixty-two chemical composition patents and three of drug candidates enter clinical trials during his tenure at National Health Research Institutes.

In the past 40 years has been in the area of cancer virology and cancer biology. Dr. Hsing-Jien Kung have made several critical discoveries in prostate cancer biology and therapeutics, epigenetics and metabolism, oncogenes retrovirology, and her pesvirology.

Dr. Shia’s research interests are centralized on three major areas: （1） development of antiviral and antibiotic agents against local and/or global infectious diseases （e.g., EV-71 and MRSA）; （2） development of agents for treating metabolic disorders （e.g., T2D） based on novel molecular targets （e.g., peripheral CB1 receptors）; （3） development of CXCR4-targeting stem cell mobilizers for tissue repair （e.g., AKI）, ischaemic diseases （e.g., IS, HCC, mTBI and MI） as well as peripheral blood stem cell transplantation （PBSCT）. In parallel, his laboratories also maintain a high momentum on developing new synthetic methodologies and total synthesis of natural products with structural complexity and/or diverse bioactivities.